权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

NEW METHOD FOR QSAR FOR BIOPHARMACEUTICAL PRODUCTS

生物制药产品 QSAR 的新方法

基本信息

批准号：
2024603
负责人：
BORIS Y ZASLAVSKY
金额：
$ 9.46万
依托单位：
ANALIZA, INC.
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-08-01 至 1998-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2024603
关键词：
acidity /alkalinity analytical chemistry biological products chemical structure function drug /agent drug design /synthesis /production drug screening /evaluation hydropathy method development protein structure function

项目摘要

This innovation is aimed at providing a new methodology for quantitative structure-activity relationships (QSAR) analysis of biopharmaceutical agents. Analysis of quantitative structure-activity relationships is fundamentally important for rational drug design. While QSAR analysis is widely used for common dugs, it is virtually non-existent for various technical reason for biologically active therapeutic agents. ANALIZA is proposing to develop and validate a new methodology for quantitatie measurements of hydrophobic properties useful for QSAR of biopharmaceuticals, such as peptides, proteins, oligonucleotides, etc. The proposed methodology is unique ( in regard to the type of information obtained), quantitative and universal ( in that may be used for comparison of compounds of completely different chemical nature and structure), inexpensive and easy to perform (and thus a viable and cost effective alternative to current structure optimization techniques). Phase I portion of this SBIR program is designed to validate the feasibility of he proposed methodology via a direct demonstration of a QSAR analysis as applied to a series of structurally different peptides and proteins with varied biological activities as provided by biopharmaceutical partners. PROPOSED COMMERCIAL APPLICATION: A new methodology for application of quantitative structure-activity relationship (QSAR) analysis to biological therapeutic agents would improve rational design of chemical modifications beneficial for manufacturing of biological therapeutic agents with improved efficacy, safety, and stability. It should thus provide a new powerful tool for timely advancements in the rapidly growing field of biopharmaceuticals.

这一创新旨在提供一种新的定量方法，生物药物构效关系（QSAR）分析剂. 定量构效关系分析是对合理的药物设计至关重要。 QSAR分析被广泛用于普通的挖掘，它实际上是不存在的各种生物活性治疗剂技术原因。 Analiza是建议开发和验证一种新的定量方法，疏水性能的测量，用于定量构效关系的生物药物，如肽、蛋白质、寡核苷酸等。拟议的方法是独特的（就信息类型而言获得）、定量和普遍（因为可以用于化学性质完全不同的化合物的比较，结构）、廉价且易于执行（因此是可行的且成本当前结构优化技术的有效替代方案）。该SBIR计划的第一阶段部分旨在验证他提出的方法的可行性，通过直接示范一个应用于一系列结构不同的肽的QSAR分析和具有不同生物活性的蛋白质，生物制药合作伙伴拟定商业应用：定量构效关系应用的新方法与生物治疗剂的关系（QSAR）分析将改进化学改性合理设计，制备具有改善功效的生物治疗剂，安全和稳定。因此，它应该提供一个新的强大工具，在快速发展的生物制药领域及时取得进展。